Scarica l'app Stockscreener
22.74
5.21%
-1.26
Precedente Chiudi:
$24.00
Aprire:
$23.86
Volume 24 ore:
17,283
Relative Volume:
0.08
Capitalizzazione di mercato:
$617.47M
Reddito:
-
Utile/perdita netta:
$11.77M
Rapporto P/E:
-146.99
EPS:
-0.1547
Flusso di cassa netto:
$-19.23M
1 W Prestazione:
-15.36%
1M Prestazione:
-19.63%
6M Prestazione:
+62.15%
1 anno Prestazione:
+29.33%
Intervallo 1D:
$22.81
$24.36
Intervallo di 1 settimana:
$22.81
$26.83
Portata 52W:
$12.12
$48.31
Tourmaline Bio Inc Stock (TRML) Company Profile
Nome
Tourmaline Bio Inc
Settore
Industria
Telefono
646-481-9832
Indirizzo
27 WEST 24TH STREET, NEW YORK
Confronta TRML con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| TRML | 22.93 | 617.47M | 0 | 11.77M | -19.23M | -0.1547 |
| VRTX | 446.50 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.51 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.80 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.97 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.80 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-15 | Iniziato | Jefferies | Buy |
| 2023-12-04 | Ripresa | H.C. Wainwright | Buy |
| 2023-11-17 | Iniziato | Truist | Buy |
| 2023-10-31 | Iniziato | Guggenheim | Buy |
| 2023-10-25 | Iniziato | Piper Sandler | Overweight |
| 2022-10-20 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Mostra tutto
Tourmaline Bio Inc Borsa (TRML) Ultime notizie
Prevent Blindness Declares Fifth Annual Thyroid Eye Disease Awareness Week as Nov. 18-24, 2024 - InvisionMag
This Week in Ophthalmology: Week of November 11, 2024 - Ophthalmology Times
Blue Owl Capital Holdings LP Adjusts Stake in Tourmaline Bio Inc - GuruFocus.com
HC Wainwright Reduces Earnings Estimates for Tourmaline Bio - Defense World
HC Wainwright Lowers Earnings Estimates for Tourmaline Bio - MarketBeat
Tourmaline Bio Sets Key Investor Day with Focus on Pacibekitug Development | TRML Stock News - StockTitan
Alternus Clean Energy Inc (NASDAQ:ALCE) Sees Significant Decrease in Short Interest - Defense World
Alchemy Investments Acquisition Corp 1 (NASDAQ:ALCY) Short Interest Update - Defense World
Short Interest in Alchemy Investments Acquisition Corp 1 (NASDAQ:ALCYW) Decreases By 97.6% - Defense World
Tourmaline Bio (NASDAQ:TRML) Price Target Raised to $49.00 - Defense World
Greenlane Renewables (OTCMKTS:GRNWF) Trading 21.2% Higher – Here’s What Happened - Defense World
Tourmaline Bio ATM - SVB Leerink
Varonis Systems, Inc. (NASDAQ:VRNS) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Tourmaline Bio, Inc. Reports Third Quarter Financial Results - TipRanks
Tourmaline Bio (NASDAQ:TRML) Price Target Raised to $49.00 at HC Wainwright - MarketBeat
Tourmaline Bio Inc (TRML) Quarterly 10-Q Report - Quartzy
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
AlphaCentric Advisors LLC Sells 69,500 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat
Tourmaline Bio shares get buy rating on IL-6 study optimism - Investing.com Canada
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DICE, Q - GuruFocus.com
The Best Curling Irons, Based On Several Months Of Testing - Forbes
Tourmaline Bio to Present at Upcoming Investor Conferences - The Manila Times
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Update - Defense World
Short Interest in Tourmaline Bio, Inc. (NASDAQ:TRML) Declines By 20.0% - MarketBeat
Cantor Fitzgerald Predicts Tourmaline Bio FY2024 Earnings - Defense World
Tourmaline Bio, Inc. to Post FY2024 Earnings of ($2.85) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:TRML) - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Shares Up 6.3%Here's What Happened - MarketBeat
Tourmaline Bio Insiders Placed Bullish Bets Worth US$643.3k - Simply Wall St
Keros Therapeutics appoints new Chief Medical Officer - Investing.com
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer - GlobeNewswire
Cantor Fitzgerald Upgrades Tourmaline Bio (NASDAQ:TRML) to Strong-Buy - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Shares Gap UpStill a Buy? - MarketBeat
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024 - The Manila Times
Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference - The Manila Times
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in ... - The Bakersfield Californian
TRMLTourmaline Bio, Inc. Latest Stock News & Market Updates - StockTitan
Investing in Tourmaline Bio Inc (TRML): What You Must Know - Knox Daily
Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting (NASDAQ:TRML) - Seeking Alpha
Cubist Systematic Strategies LLC Purchases Shares of 37,861 Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat
Tourmaline Bio (NASDAQ:TRML) Shares Gap Down – Time to Sell? - Defense World
Tourmaline Bio (NASDAQ:TRML) Shares Gap DownTime to Sell? - MarketBeat
Guggenheim reiterates Buy on Tourmaline Bio shares, keeps price target By Investing.com - Investing.com UK
Tourmaline Bio to present research at Cardiometabolic Congress By Investing.com - Investing.com South Africa
Tourmaline Bio to present research at Cardiometabolic Congress - Investing.com
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress - The Manila Times
Tourmaline Bio announces CMO resignation By Investing.com - Investing.com South Africa
Tourmaline Bio announces CMO resignation - Investing.com India
Tourmaline Bio’s Chief Medical Officer Resigns Amicably - TipRanks
Tourmaline Bio, Inc. Announces Resignation of Yung Chyung as Chief Medical Officer,Effective October 31, 2024 - Marketscreener.com
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Marquette Asset Management LLC Raises Stake in Vera Bradley, Inc. (NASDAQ:VRA) - Defense World
Tourmaline Bio Inc Azioni (TRML) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tourmaline Bio Inc Azioni (TRML) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kulkarni Sandeep Chidambar | CEO |
Aug 16 '24 |
Buy |
13.79 |
5,221 |
71,998 |
5,221 |
| MCDADE MARK | Director |
Jan 29 '24 |
Buy |
32.50 |
100,000 |
3,250,000 |
448,431 |
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):